AlphAIAlphAI — Financial news for AI agents
pharmexec.comNOV 33 min read$TEVA

Teva Licenses U.S. Rights to Infliximab, Etanercept Biosimilars

Teva Pharmaceuticals and Samsung Bioepis agreed to license and commercialize two FDA-approved biosimilars in the U.S. Teva will handle sales, with Samsung retaining manufacturing. The deal includes upfront payments, milestones, and profit sharing. Closing is expected by the end of 2026, with rights to etanercept-ykro transferring at that time and infliximab-abda in Q3 2027.

Original reporting
pharmexec.com
Published Nov 3, 2026, 2:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 3:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Teva Licenses U.S. Rights to Infliximab, Etanercept Biosimilars — source image
Source · pharmexec.com
Decision brief

The 30-second read

$TEVANeutralMed
01

Why it matters

The agreement expands Teva's product pipeline but financial upside is uncertain until launch and pricing are set.

02

Market read

First‑report of a licensing deal that could add revenue streams for Teva and increase competition in the U.S. biosimilar market.

03

What to watch

Milestone payments and profit‑share terms are undisclosed; payer coverage and competitive pricing will drive actual impact.

Relevance 7/10Novelty 7/10Timing: today

Background

Teva is pursuing its "Pivot to Growth" strategy to expand its biosimilar portfolio. Samsung Bioepis retains manufacturing and regulatory oversight.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

Teva announced a licensing and commercialization agreement to obtain U.S. rights to two FDA‑approved biosimilars, infliximab‑abda and etanercept‑ykro.

Expected impact

potential modest upside as investors price in future sales and profit‑share upside

Evidence & confidence

No financial terms disclosed; market will assess upside based on expected launch timing and competitive positioning.

Market effects

Sector

Adds competition in the U.S. biosimilar anti‑TNF market, may pressure pricing for existing products.

Regional

Strengthens Teva's U.S. immunology footprint while leveraging Samsung Bioepis' manufacturing.

Global

Highlights growing cross‑border biosimilar collaborations, could influence global supply dynamics.

Counterpoint

What could challenge this read

If launch delays or pricing pressure materialize, the deal could weigh on Teva's margin expectations.

Key entities

  • company
    Teva Pharmaceutical Industries

    US‑listed pharmaceutical company acquiring U.S. rights to two biosimilars.

  • company
    Samsung Bioepis

    Korean biotech partner retaining manufacturing and regulatory responsibilities.

Read at source← All news

StoryTeva licenses U.S. rights to two Samsung Bioepis biosimilars in $420 million deal

Also covered by

2 outlets

Related articles

NOV 3
$TEVAHighAI 9/10

Teva Q3 2026 slides: biopharma shift lifts margins to 58.7%

Teva Pharmaceuticals (NYSE:TEVA) reported Q3 2026 revenues of $4.4B and adjusted EPS of $0.86, beating estimates. Gross margin rose to 58.7% due to a shift toward biopharma. Key products like AUSTEDO, UZEDY, and AJOVY drove growth. The company raised full-year guidance and announced FDA approval for WELTRUZA, a new schizophrenia treatment.

investing.com3 min
NOV 3
$TEVAHighAI 9/10

Teva again raises guidance as branded drugs lift revenue

Teva Pharmaceutical (TEVA) reported Q3 revenue of $4.4B, beating estimates. It raised 2026 revenue guidance to $16.7-$17B. Branded drugs grew 33%, with Austedo, Ajovy, and Uzedy driving sales. GAAP net profit was $233M, while non-GAAP was $1B. Debt refinancing extended maturity to 6.3 years. CEO highlighted FDA approvals and biosimilars agreement with Samsung Bioepis.

en.globes.co.il5 min
NOV 3
$QUREMed

UniQure gets an FDA decision date; Teva scraps brain drug study

UniQure's Huntington's disease gene therapy application is under FDA review with a decision expected by May 1. Teva Pharmaceuticals halted a mid-stage study of emrusolmin for multiple system atrophy due to futility. Bright Minds Biosciences' antiseizure drug trial was partially halted by the FDA. Specific Biologics raised $35M in Series A funding for ALS therapy trials. CinRx Pharma and Graviton BioScience formed a joint venture to develop cardiovascular drugs.

finance.yahoo.com6 min
NOV 3
$TEVAHighAI 8/10

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA): Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial…

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA™ LAUNCH AND STRATEGIC ADDITION

SEC EDGAR 8-K2 min